アフターアワーズ： 3.44

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX) 最新ニュース

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX) 最新ニュース

Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Yahoo Finance

Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat

Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Public Employees Retirement Association of Colorado - Defense World

DNA Repair Drugs Market Freshly Published Findings Size, Key Manufacturers, Demand Analysis, Share And Over... - WhaTech

WORK Medical Technology Group LTD Ordinary Shares' Quiet Period Set To End on October 2nd (NASDAQ:WOK) - MarketBeat

Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR

Silexion reports improved outcomes in pancreatic cancer trial - Investing.com India

A stock that deserves closer examination: Replimune Group Inc (REPL) - US Post News

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - StockTitan

Repare Therapeutics keeps Buy rating, stock target on updated trial results - Investing.com Canada

Repare Therapeutics reports key biomarkers linked to ovarian, endometrial cancer prognosis - Investing.com

Press Release Service: Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - CRISPR Medicine News

RPTXRepare Therapeutics Inc. Common Shares Latest Stock News & Market Updates - StockTitan

Repare Therapeutics' (RPTX) Buy Rating Reiterated at HC Wainwright - MarketBeat

Repare Therapeutics (NASDAQ:RPTX) Receives Buy Rating from HC Wainwright - Defense World

Repare Therapeutics reports key biomarkers linked to ovarian, endometrial cancer prognosis - Investing.com India

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - StockTitan

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Analysts - Defense World

Biopharma Layoff Tracker 2024: AGC Biologics, Oncternal, Biosense Webster and More Cut Staff - BioSpace

Its Stock Has Paid Off Big Time For Replimune Group Inc - SETE News

Purple Biotech Reports Additional Positive Interim Data - GlobeNewswire

Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright - Defense World

Analytical Lens: Exploring Replimune Group Inc (REPL)’s Financial Story Through Ratios - The Dwinnex

Pixelworks (PXLW) and Universal Pictures Enter Agreement for TrueCut Motion Technology - StreetInsider.com

Replimune Group (NASDAQ:REPL) Stock Price Down 6.4% - MarketBeat

Repare Therapeutics Inc. (NASDAQ:RPTX) institutional owners may be pleased with recent gains after 68% loss over the past year - Simply Wall St

Acadian Asset Management LLC Acquires 284,036 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat

H.C. Wainwright maintains Buy rating on Replimune shares - Investing.com India

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Yahoo Finance

Acadian Asset Management LLC Purchases 284,036 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - StockTitan

Repare Therapeutics Inc. Forecasted to Post FY2024 Earnings of ($1.94) Per Share (NASDAQ:RPTX) - MarketBeat

Bloom Burton Comments on Repare Therapeutics Inc.’s FY2024 Earnings (NASDAQ:RPTX) - Defense World

Repare Therapeutics Inc. to Post FY2025 Earnings of ($2.79) Per Share, Bloom Burton Forecasts (NASDAQ:RPTX) - Defense World

Bloom Burton Weighs in on Repare Therapeutics Inc.'s FY2025 Earnings (NASDAQ:RPTX) - MarketBeat

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - StockTitan

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - StockTitan

Q3 2024 Earnings Estimate for Repare Therapeutics Inc. Issued By HC Wainwright (NASDAQ:RPTX) - Defense World

Repare Therapeutics Inc. to Post Q3 2024 Earnings of ($0.85) Per Share, HC Wainwright Forecasts (NASDAQ:RPTX) - MarketBeat

Repare Therapeutics divulges a novel strategy for BRCA-mutated tumors - BioWorld Online

Repare Therapeutics (NASDAQ:RPTX) Given Buy Rating at HC Wainwright - Defense World

Repare Therapeutics stock hits 52-week low at $2.76 - Investing.com

Repare Therapeutics' (RPTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Repare Therapeutics stock hits 52-week low at $2.76 By Investing.com - Investing.com UK

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data (RPTX) - Seeking Alpha

Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic Landscape - MSN

Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - MedCity News

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets - Clinical Trials Arena

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets - Yahoo Finance

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets - Pharmaceutical Technology

Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape - Insider Monkey

Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape - Yahoo Finance

Montreal-Cambridge biotech to lay off 25% of team - The Business Journals

Layoffs at BioMarin, Repare - BioCentury

Repare Therapeutics to Cut Quarter of Workforce in Strategic Shift - MarketWatch

Repare Therapeutics Announces Strategic R&D Focus and Workforce Reduction - TipRanks

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio - Yahoo Finance UK

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio - Business Wire

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates - MSN

Repare Therapeutics to Participate in Two Upcoming Investor Conferences - Yahoo Finance UK

Repare Therapeutics to Participate in Two Upcoming Investor Conferences - Business Wire

Repare Therapeutics to Participate in Two Upcoming Investor Conferences - StockTitan

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Sold by Sumitomo Mitsui Trust Holdings Inc. - Defense World

Research Analysts Offer Predictions for Repare Therapeutics Inc.'s FY2028 Earnings (NASDAQ:RPTX) - MarketBeat

FY2028 Earnings Estimate for Repare Therapeutics Inc. Issued By Capital One Financial (NASDAQ:RPTX) - Defense World

Repare Therapeutics announces board reshuffle By Investing.com - Investing.com Canada

Repare Therapeutics (NASDAQ:RPTX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

Repare Therapeutics stock hits 52-week low at $2.95 - Investing.com

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results - CRISPR Medicine News

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results - StockTitan

RPTXに似た銘柄